Eton Pharmaceuticals launches IMPAVIDO for leishmaniasis By Investing.com
Investing.com Canada
Eton Pharmaceuticals (NASDAQ:ETON) has launched IMPAVIDO (miltefosine) capsules in the United States, for which it now holds exclusive commercialization rights. The drug is indicated for the treatment of various forms of leishmaniasis in adults and adolescents aged 12 and older weighing at least 30 kg. Eton has implemented a patient support program, Eton Cares, and centralized distribution through Anovo Specialty Pharmacy.
Read the full story
This is a short summary. The complete article is published by Investing.com Canada.
Headline and summary aggregated from public news feeds. For information only — not financial advice.